Half of the new Danish employees will be in R&D roles

Danish insulin and diabetes specialist Novo Nordisk says it intends to employ 6000 more highly skilled workers within Denmark by 2022. Half of these new staff will work in R&D. The announcement bucks the trend of recent years in pharma, which has tended to see companies downsizing drastically and closing R&D sites.

The company used its announcement to call on the Danish government to prioritise investment in research-based training in the sciences to ensure that research-driven Danish companies can continue to grow. ‘It will be crucial for Novo Nordisk that Denmark educates world-class graduates but also focuses far more intently on attracting international talent,’ said the firm’s chief science officer, Mads Krogsgaard Thomsen in a statement.